Kirkland & Ellis LLP
10/23/2025 | Press release | Distributed by Public on 10/23/2025 11:17
Kirkland Advises Curewell Capital on Investment in Wilmington PharmaTech
Kirkland & Ellis advised private equity firm Curewell Capital on its investment in Wilmington PharmaTech (WPT), a U.S.-based specialty contract research, development and manufacturing organization focused on custom small molecule API development and manufacturing organization. Hui-Yin "Harry" Li, Ph.D., Founder and CEO of WPT, will retain a significant ownership stake and will continue to lead the business alongside the management team. The partnership with Curewell will provide significant growth capital to expand WPT's manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the U.S. The transaction was announced October 21, 2025.
Read the transaction press release
The Kirkland team included corporate lawyers Adam Wexner, Marion Racine, Jane Guo and Yangxier Sui; tax lawyers Rachel Cantor and Rory Minnis; debt finance lawyers Michelle Kilkenney and Alex Bender; and healthcare lawyers Dennis Williams, Will Richmond and Brian King.
Kirkland & Ellis LLP published this content on October 23, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 23, 2025 at 17:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]